- Gingival pain: an unusual side effect of ziprasidone.
Gingival pain: an unusual side effect of ziprasidone.
BMJ case reports (2013-01-04)
Ashwati Raghunath
PMID23283612
ABSTRAKT
The patient is a 52-year-old man with schizophrenia who developed severe, unremitting gingival pain after his ziprasidone dosage was increased from 80 to 120 mg. His physical examination and laboratory findings were unremarkable. He did not have any extra-pyramidal side effects. His pain did not ameliorate after taking acetaminophen and non-steroidal anti-inflammatory drugs. As a last resort, the patient took benztropine and his pain subsided within half an hour. His ziprasidone dosage was decreased and the patient is currently doing well. He has not experienced gingival pain since his medication was adjusted.
MATERIAŁY
Numer produktu
Marka
Opis produktu
Sertraline hydrochloride, European Pharmacopoeia (EP) Reference Standard
Sertraline for system suitability, European Pharmacopoeia (EP) Reference Standard
Sertraline for peak identification, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Sodium bicarbonate, powder, BioReagent, for molecular biology, suitable for cell culture, suitable for insect cell culture
Sigma-Aldrich
Sodium bicarbonate solution, solution (7.5%), sterile-filtered, BioReagent, suitable for cell culture
Sigma-Aldrich
Rifampicin, suitable for plant cell culture, BioReagent, ≥95% (HPLC), powder or crystals
Supelco
Calcium standard for AAS, analytical standard, 1.000 g/L Ca+2 in hydrochloric acid, traceable to BAM
Pyridostigmine bromide, European Pharmacopoeia (EP) Reference Standard
Trihexyphenidyl hydrochloride, European Pharmacopoeia (EP) Reference Standard
Triamcinolone acetonide, European Pharmacopoeia (EP) Reference Standard
Dextropropoxyphene for system suitability, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Sodium bicarbonate, puriss., meets analytical specification of Ph. Eur., BP, USP, FCC, E500, 99.0-100.5%, powder